<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02365922</url>
  </required_header>
  <id_info>
    <org_study_id>ARTFL8101</org_study_id>
    <secondary_id>1U54NS092089-01</secondary_id>
    <nct_id>NCT02365922</nct_id>
  </id_info>
  <brief_title>Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL)</brief_title>
  <acronym>ARTFL</acronym>
  <official_title>Rare Diseases Clinical Research Network Advancing Research and Treatment for Frontotemporal Lobar Degeneration [ARTFL]: Research Projects 1 &amp; 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Advancing Translational Science (NCATS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Bluefield Project</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tau Consortium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Frontotemporal Lobar Degeneration (FTLD) is the neuropathological term for a collection of
      rare neurodegenerative diseases that correspond to four main overlapping clinical syndromes:
      frontotemporal dementia (FTD), primary progressive aphasia (PPA), corticobasal degeneration
      syndrome (CBS) and progressive supranuclear palsy syndrome (PSPS). The goal of this study is
      to build a FTLD clinical research consortium to support the development of FTLD therapies for
      new clinical trials. The consortium, referred to as Advancing Research and Treatment for
      Frontotemporal Lobar Degeneration (ARTFL), will be headquartered at UCSF and will partner
      with six patient advocacy groups to manage the consortium. Participants will be evaluated at
      14 clinical sites throughout North America and a genetics core will genotype all individuals
      for FTLD associated genes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Frontotemporal Lobar Degeneration (FTLD) is the neuropathological term for a collection of
      rare neurodegenerative diseases that correspond to four main overlapping clinical syndromes:
      frontotemporal dementia (FTD), primary progressive aphasia (PPA), corticobasal degeneration
      syndrome (CBS) and progressive supranuclear palsy syndrome (PSPS). The goal of this study is
      to build a FTLD clinical research consortium (FTLD CRC) to support the development of FTLD
      therapies for new clinical trials. The FTLD CRC will be headquartered at UCSF and will
      partner with six patient advocacy groups to manage the consortium. Patients will be evaluated
      at 13 clinical sites throughout North America and a genetics core will genotype all
      individuals for FTLD associated genes.

      The study will be divided into 2 projects. The first project will be Preparing for Sporadic
      FTLD Clinical Trials and the second project will be a Longitudinal Assessment of Familial
      FTLD. Self-registration for an online registry will be available for patients and families
      with any FTLD syndrome. Eligible participants for research Projects 1 and 2 FTLD will be
      invited to a CRC site for clinical evaluations. All enrolled participants in both research
      projects will have a site visit consisting of a neurological exam, medical and family
      history, cognitive testing, and a blood draw.

      Participants in Project 1 who have a diagnosis of Progressive Supranuclear Palsy Syndrome
      will have two additional assessments. A lumbar puncture (LP) will be performed for CSF
      collection, and an MRI scan of the brain will be done.

      Participants in Project 2: Longitudinal Assessment of familial FTLD will return for a
      follow-up visit in 12 months; procedures at the follow-up visit will be identical to those at
      baseline. Additionally, asymptomatic participants will undergo MRI scans at both visits.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Scores of UDS FTLD Module Tests</measure>
    <time_frame>Baseline, 12 mo.</time_frame>
    <description>Neuropsychological test scores from the Uniform Data Set FTLD Module will be collected and compared across patient populations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progressive Supranuclear Palsy Rating Scale (PSPRS)</measure>
    <time_frame>Baseline</time_frame>
    <description>Scores will be compared among patient populations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuroimaging</measure>
    <time_frame>Baseline; 12 months</time_frame>
    <description>In asymptomatic family members of FTLD patients, changes from baseline neuroimaging will be assessed 12 months later.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1560</enrollment>
  <condition>FTLD</condition>
  <condition>Progressive Supranuclear Palsy (PSP)</condition>
  <condition>Frontotemporal Dementia (FTD)</condition>
  <condition>Corticobasal Degeneration (CBD)</condition>
  <condition>PPA Syndrome</condition>
  <condition>Behavioral Variant Frontotemporal Dementia (bvFTD)</condition>
  <condition>Semantic Variant Primary Progressive Aphasia (svPPA)</condition>
  <condition>Nonfluent Variant Primary Progressive Aphasia (nfvPPA)</condition>
  <condition>FTD With Amyotrophic Lateral Sclerosis (FTD/ALS)</condition>
  <condition>Amyotrophic Lateral Sclerosis (ALS)</condition>
  <condition>Oligosymptomatic PSP (oPSP)</condition>
  <condition>Corticobasal Syndrome (CBS)</condition>
  <arm_group>
    <arm_group_label>Patients with FTLD or family members</arm_group_label>
    <description>Participants with FTLD syndrome diagnoses and/or strong family histories of FTLD.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma, serum, cell lines and cerebrospinal fluid will be retained by study investigators and
      stored at NIH-funded repositories.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a diagnosis of a frontotemporal lobar degeneration (FTLD) syndrome, including
        progressive supranuclear palsy (PSP), semantic variant primary progressive aphasia (svPPA),
        and frontotemporal dementia with amyotrophic lateral sclerosis (FTD-ALS). Family members of
        patients with FTLD syndromes.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        1. Inclusion Criteria:Must meet one of the following research diagnostic criteria for a
             Frontotemporal lobar degeneration (FTLD) syndrome: behavioral variant frontotemporal
             dementia (bvFTD), primary progressive aphasia (PPA), semantic variant primary
             progressive aphasia (svPPA), nonfluent variant primary progressive aphasia (nfvPPA),
             frontotemporal dementia with amyotrophic lateral sclerosis (FTD/ALS), amyotrophic
             lateral sclerosis alone, corticobasal syndrome (CBS), progressive supranuclear palsy
             (PSP) or oligosymptomatic PSP (oPSP), or have a strong family history of FTLD
             syndromes.

          2. Between 18 and 85 (inclusive) years of age.

          3. Able to walk (with assistance) at the time of enrollment.

          4. Have a reliable study partner who can provide an independent evaluation of
             functioning.

          5. Speak English or Spanish

          6. Have Mini Mental State Exam (MMSE) scores between 15 - 30 (inclusive).

        Exclusion Criteria:

          1. Known presence of a structural brain lesion (e.g. tumor,cortical infarct) that could
             reasonably explain symptoms in a symptomatic participant without a known f-FTLD
             causing mutation.

          2. Known presence of an Alzheimer's disease causing mutation in PSEN1, PSEN2 or APP; or
             neuropathological evidence for Alzheimer's disease as a cause of syndrome (from brain
             biopsy).

          3. A previous history of Korsakoff encephalopathy, severe alcohol dependence (within 5
             years of onset of dementia), frequent alcohol or other substance intoxication, or
             other neurological disorder (such as multiple sclerosis)

          4. Evidence through history or laboratory testing of B12 deficiency (B12 &lt; 95% of local
             laboratory's normal value), hypothyroidism (TSH &gt;150% of normal), HIV positive,renal
             failure (creatinine &gt; 2), liver failure (ALT or AST &gt; two times normal), respiratory
             failure (requiring oxygen), extra-axial brain tumor (with visible compression of the
             brain parenchyma), large cerebral infarct that could account for clinical syndrome,
             large confluent white matter lesions (grades 3 or 4, [107] significant systemic
             medical illnesses such as deteriorating cardiovascular disease;

          5. Current medication likely to affect CNS functions in the opinion of the site PI: long
             acting benzodiazepines such as diazepam (short-acting benzodiazepines are OK),
             non-SSRI antidepressants (SSRIs or trazodone are OK), no lithium, typical neuroleptics
             as listed in the Manual of Procedures, narcotics (codeine is OK, but hold 24 hours
             before neuropsychological testing), anticonvulsants (outside of therapeutic ranges),
             antihistamines (if taking greater than three times per week; hold 24 hours before
             neuropsychological testing).

          6. In the site investigator's opinion, the participant cannot complete sufficient key
             study procedures, or equivalent assessment of impairment level.

          7. For groups where MRI scans are planned procedures, any contraindication for MRI
             scanning, such as pacemaker or other implanted metals.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adam L Boxer, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Study PI</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reilly Dever, BA</last_name>
    <phone>415-476-0670</phone>
    <email>Reilly.Dever@ucsf.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ping Wang, MA</last_name>
    <phone>415-502-7518</phone>
    <email>pwang@ucsf.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily McKinley, MSPH</last_name>
      <phone>205-996-3659</phone>
      <email>emckinley@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Erik Roberson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elvira Jimenez</last_name>
      <phone>310-478-3711</phone>
      <phone_ext>40584</phone_ext>
      <email>elvira@ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Yvette Bordelon, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Veronica Lopez</last_name>
      <phone>858-822-5786</phone>
      <email>vllopez@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Irene Litvan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reilly Dever, BA</last_name>
      <phone>415-476-0670</phone>
      <email>Reilly.Dever@ucsf.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ping Wang, MA</last_name>
      <phone>415-502-7518</phone>
      <email>pwang@ucsf.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Adam Boxer, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dana Haley</last_name>
      <phone>904-953-9680</phone>
      <email>Haley.Dana@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Neill Graff-Radford, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bita Rad</last_name>
      <phone>312-503-1925</phone>
      <email>bita.rad@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Sandra Weintraub, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann Fishman</last_name>
      <phone>410-502-5816</phone>
      <email>ann.fishman@jhu.edu</email>
    </contact>
    <investigator>
      <last_name>Chiadi U Onyike, MD, MHS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Harvard University Massachusetts General Hospital</name>
      <address>
        <city>Charlestown</city>
        <state>Massachusetts</state>
        <zip>02129</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samantha Krivensky</last_name>
      <phone>617-726-6205</phone>
      <email>skrivensky@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Bradford C Dickerson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruth Kraft</last_name>
      <phone>507-538-9487</phone>
      <email>Kraft.Ruth@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Bradley F Boeve, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Davis S Knopman, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynne Jones</last_name>
      <phone>314-362-8420</phone>
      <email>jonesly@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Nupur Ghoshal, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Masood Manoochehehri</last_name>
      <phone>212-305-5710</phone>
      <email>mm2626@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Edward D Huey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Ferrall</last_name>
      <phone>919-962-8852</phone>
      <email>jferrall@neurology.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Daniel Kaufer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frances Lissemore, PhD</last_name>
      <phone>216-464-6203</phone>
      <email>Frances.Lissemore@UHhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Brian Appleby, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-4283</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Ray, MSW</last_name>
      <phone>215-349-5873</phone>
      <email>rayc@mail.med.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Murray Grossman, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jana Windsor</last_name>
      <phone>214-648-8543</phone>
      <email>Jana.windsor@utsouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Diana Kerwin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington Harborview Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Caso</last_name>
      <phone>206-221-9038</phone>
      <email>cdcaso@uw.edu</email>
    </contact>
    <investigator>
      <last_name>Kimiko Domoto-Reilly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6T 2B5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pheth Sengdy, BSc, CCRP</last_name>
      <phone>604-822-7989</phone>
      <email>Pheth.Sengdy@vch.ca</email>
    </contact>
    <investigator>
      <last_name>Robin Hsiung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ian Mackenzie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Toronto</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Behnaz Ghazanfari, MD, CCRP</last_name>
      <phone>416-603-5800</phone>
      <phone_ext>5910</phone_ext>
      <email>Behnaz.Ghazanfari@uhnresearch.ca</email>
    </contact>
    <investigator>
      <last_name>Maria Carmela Tartaglia, MD, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Boxer AL, Knopman DS, Kaufer DI, Grossman M, Onyike C, Graf-Radford N, Mendez M, Kerwin D, Lerner A, Wu CK, Koestler M, Shapira J, Sullivan K, Klepac K, Lipowski K, Ullah J, Fields S, Kramer JH, Merrilees J, Neuhaus J, Mesulam MM, Miller BL. Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2013 Feb;12(2):149-56. doi: 10.1016/S1474-4422(12)70320-4. Epub 2013 Jan 2.</citation>
    <PMID>23290598</PMID>
  </reference>
  <reference>
    <citation>Boxer AL, Garbutt S, Seeley WW, Jafari A, Heuer HW, Mirsky J, Hellmuth J, Trojanowski JQ, Huang E, DeArmond S, Neuhaus J, Miller BL. Saccade abnormalities in autopsy-confirmed frontotemporal lobar degeneration and Alzheimer disease. Arch Neurol. 2012 Apr;69(4):509-17. doi: 10.1001/archneurol.2011.1021.</citation>
    <PMID>22491196</PMID>
  </reference>
  <reference>
    <citation>Boxer AL, Lang AE, Grossman M, Knopman DS, Miller BL, Schneider LS, Doody RS, Lees A, Golbe LI, Williams DR, Corvol JC, Ludolph A, Burn D, Lorenzl S, Litvan I, Roberson ED, Höglinger GU, Koestler M, Jack CR Jr, Van Deerlin V, Randolph C, Lobach IV, Heuer HW, Gozes I, Parker L, Whitaker S, Hirman J, Stewart AJ, Gold M, Morimoto BH; AL-108-231 Investigators. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol. 2014 Jul;13(7):676-85. doi: 10.1016/S1474-4422(14)70088-2. Epub 2014 May 27.</citation>
    <PMID>24873720</PMID>
  </reference>
  <reference>
    <citation>Rosen HJ, Alcantar O, Zakrzewski J, Shimamura AP, Neuhaus J, Miller BL. Metacognition in the behavioral variant of frontotemporal dementia and Alzheimer's disease. Neuropsychology. 2014 May;28(3):436-47. doi: 10.1037/neu0000012. Epub 2014 Feb 17.</citation>
    <PMID>24548124</PMID>
  </reference>
  <reference>
    <citation>Rosen HJ, Alcantar O, Rothlind J, Sturm V, Kramer JH, Weiner M, Miller BL. Neuroanatomical correlates of cognitive self-appraisal in neurodegenerative disease. Neuroimage. 2010 Feb 15;49(4):3358-64. doi: 10.1016/j.neuroimage.2009.11.041. Epub 2009 Dec 1.</citation>
    <PMID>19961939</PMID>
  </reference>
  <reference>
    <citation>Rohrer JD, Rosen HJ. Neuroimaging in frontotemporal dementia. Int Rev Psychiatry. 2013 Apr;25(2):221-9. doi: 10.3109/09540261.2013.778822. Review.</citation>
    <PMID>23611351</PMID>
  </reference>
  <reference>
    <citation>Boeve BF. Progressive supranuclear palsy. Parkinsonism Relat Disord. 2012 Jan;18 Suppl 1:S192-4. doi: 10.1016/S1353-8020(11)70060-8. Review.</citation>
    <PMID>22166432</PMID>
  </reference>
  <reference>
    <citation>Boeve BF. The multiple phenotypes of corticobasal syndrome and corticobasal degeneration: implications for further study. J Mol Neurosci. 2011 Nov;45(3):350-3. doi: 10.1007/s12031-011-9624-1. Epub 2011 Aug 19. Review.</citation>
    <PMID>21853287</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 11, 2015</study_first_submitted>
  <study_first_submitted_qc>February 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2015</study_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FTLD, PSP, CBD, PPA, FTD, FTD-ALS, CBS, ALS, svPPA, nfvPPA, oPSP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Aphasia</mesh_term>
    <mesh_term>Supranuclear Palsy, Progressive</mesh_term>
    <mesh_term>Frontotemporal Dementia</mesh_term>
    <mesh_term>Aphasia, Primary Progressive</mesh_term>
    <mesh_term>Pick Disease of the Brain</mesh_term>
    <mesh_term>Frontotemporal Lobar Degeneration</mesh_term>
    <mesh_term>Primary Progressive Nonfluent Aphasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

